{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:27:17Z","timestamp":1768548437343,"version":"3.49.0"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["F30CA196199"],"award-info":[{"award-number":["F30CA196199"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS08541"],"award-info":[{"award-number":["R01NS08541"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U01NS090284"],"award-info":[{"award-number":["U01NS090284"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA177476"],"award-info":[{"award-number":["R01CA177476"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS086943"],"award-info":[{"award-number":["R01NS086943"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS099463"],"award-info":[{"award-number":["R01NS099463"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0236374","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T17:31:01Z","timestamp":1596216661000},"page":"e0236374","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5387-1833","authenticated-orcid":true,"given":"Patrick C.","family":"Gedeon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Streicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5036-5820","authenticated-orcid":true,"given":"Teilo H.","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary E.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micheal P.","family":"Jokinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"pone.0236374.ref001","article-title":"A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma","author":"PC Gedeon","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"11","key":"pone.0236374.ref002","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1634\/theoncologist.2018-0179","article-title":"FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia","volume":"23","author":"ED Pulte","year":"2018","journal-title":"The oncologist"},{"issue":"18","key":"pone.0236374.ref003","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA Approval: Blinatumomab","volume":"21","author":"D Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"pone.0236374.ref004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","article-title":"FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease","volume":"25","author":"EY Jen","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"pone.0236374.ref005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"AF Labrijn","year":"2019","journal-title":"Nature reviews Drug discovery"},{"issue":"1","key":"pone.0236374.ref006","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"MS Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"pone.0236374.ref007","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"JN Brudno","year":"2016","journal-title":"Blood"},{"issue":"1","key":"pone.0236374.ref008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/0008-5472.CAN-19-1131","article-title":"Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events","volume":"80","author":"M Klinger","year":"2019","journal-title":"Cancer Res"},{"key":"pone.0236374.ref009","unstructured":"US Department of Health and Human Services Food and Drug Adminoistration. Guidance for Industry, Investigatiors, and Reviewers: Exploratory IND Studies. 2006."},{"key":"pone.0236374.ref010","unstructured":"Elson G, Dean Y, Kosco-Vilbois M, inventors; Novimmune SA, assignee. Anti-CD3 antibody formulations. USA 2006. US20070065437A1"},{"issue":"20","key":"pone.0236374.ref011","doi-asserted-by":"crossref","first-page":"9402","DOI":"10.1073\/pnas.91.20.9402","article-title":"A block in both early T lymphocyte and natural killer cell development in transgenic mice with high-copy numbers of the human CD3E gene","volume":"91","author":"B Wang","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"pone.0236374.ref012","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/intimm\/10.12.1777","article-title":"Expression of a CD3 epsilon transgene in CD3 epsilon(null) mice does not restore CD3 gamma and delta expression but efficiently rescues T cell development from a subpopulation of prothymocytes","volume":"10","author":"N Wang","year":"1998","journal-title":"International immunology"},{"key":"pone.0236374.ref013","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council of the National Academies, Institute for Laboratory Animal Research","year":"2011"},{"key":"pone.0236374.ref014","unstructured":"Maronpot RR. Pathology of the Mouse. Vienna. 1999."},{"key":"pone.0236374.ref015","volume-title":"Pathology of the Mouse: Reference and Atlas","author":"JM AE Radovsky","year":"1999"},{"issue":"1","key":"pone.0236374.ref016","first-page":"3","article-title":"3rd. Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice","volume":"79","author":"JM Ward","year":"1999","journal-title":"Lab Invest"},{"issue":"4","key":"pone.0236374.ref017","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1478-3231.1999.tb00056.x","article-title":"Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma","volume":"19","author":"K Harada","year":"1999","journal-title":"Liver"},{"key":"pone.0236374.ref018","unstructured":"Gedeon PC. Antibody-mediated Immunotherapy of Brain Tumors. Dissertation, Duke University. 2017. Available from: https:\/\/hdl.handle.net\/10161\/16227."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0236374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T17:32:02Z","timestamp":1596216722000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0236374"}},"subtitle":[],"editor":[{"given":"Ilya","family":"Ulasov","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0236374","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]}}}